By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: C3.AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against C3.ai, Inc. – AI
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Technology > C3.AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against C3.ai, Inc. – AI
C3.AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF 0,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against C3.ai, Inc. – AI
Technology

C3.AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against C3.ai, Inc. – AI

GlobeNews Wire
Last updated: 18/09/2025 9:36 AM
GlobeNews Wire
Published: 18/09/2025
Share
SHARE

NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI), if they purchased the Company’s securities between February 26, 2025 to August 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Get Help

C3 investors should visit us at https://claimsfiler.com/cases/nyse-ai-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

C3 and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 8, 2025, the Company disclosed disappointing preliminary financial results for 1Q 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing its poor sales results and lowered guidance to “the reorganization with new leadership” as well as the health ailments of its Chief Executive Officer.

On this news, the price of C3’s shares fell from a closing price of $22.13 per share on August 8, 2025 to $16.47 per share on August 11, 2025, a decline of about 25.58%.  

The case is John Liggett Sr. v. C3.ai, Inc., et al., No. 25-cv-07129.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA / SOFTAG breast implant
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
Lars Fjeldsoe-Nielsen Joins Owl Ventures as General Partner to Accelerate Global Education Investments
4DMT Announces New Employment Inducement Grants
TAGGED:100,000actionAdventureagainstalert:c3.aiclaimsfilerclassdeadlineexcessinc.investorslawsuitsleadlossesnewsplaintiffremindsshareholderwith
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Health

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

GlobeNews Wire
GlobeNews Wire
30/09/2025
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Xinhua Silk Road: Discover China with foreign friends
24/7 Market News: Kraig Labs Unlocks Spider Silk at Scale, Solving a Historical Problem for Natures Toughest Fiber
New Bounteous White Paper Maps the AI Whitespace for Business Leaders
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?